Does sertraline cause a false‑positive plasma free fractionated metanephrine assay?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Does Sertraline Cause False-Positive Plasma Free Fractionated Metanephrines?

No, sertraline does not cause false-positive plasma free fractionated metanephrine assays. The FDA drug label for sertraline specifically mentions false-positive urine immunoassay screening tests for benzodiazepines, but makes no mention of interference with metanephrine testing 1. The Endocrine Society guidelines identify medications that interfere with metanephrine measurements—specifically noting tricyclic antidepressants and drugs that directly interfere with measurement methods—but do not list selective serotonin reuptake inhibitors (SSRIs) like sertraline as problematic 2.

Key Evidence Supporting This Conclusion

Drug Class Distinctions Matter

The most recent and highest-quality research (2024) demonstrates that norepinephrine reuptake blockers (tricyclic antidepressants and serotonin-norepinephrine reuptake inhibitors) cause false-positive elevations in plasma normetanephrine and methoxytyramine, with false-positive rates rising from 4.8% to 23.0% for normetanephrine 3. Critically, this same study found that selective serotonin reuptake inhibitors did not increase plasma concentrations of metabolites 3.

Sertraline is a selective serotonin reuptake inhibitor (SSRI), not a norepinephrine reuptake blocker. This pharmacologic distinction is essential—sertraline's mechanism does not interfere with catecholamine disposition in the way that tricyclic antidepressants do.

Guideline-Based Medication Concerns

The Endocrine Society guidelines explicitly state that medications interfering with catecholamine disposition (specifically mentioning tricyclic antidepressants) can result in raised biochemical test results 2. The absence of SSRIs from this list, combined with their specific mention of tricyclics, indicates that SSRIs like sertraline are not recognized as problematic.

Clinical Implications

  • Continue sertraline during metanephrine testing: There is no need to discontinue sertraline before plasma free metanephrine testing
  • If elevated results occur: Follow standard protocols for borderline elevations, including repeat sampling in the supine position after 30 minutes of recumbency 2
  • Consider other causes: If metanephrines are elevated in a patient on sertraline, investigate other medications (particularly tricyclic antidepressants, SNRIs, α-blockers, or antipsychotics), improper sampling technique (seated vs. supine position), physiological stress, or actual pheochromocytoma/paraganglioma 3, 4, 5

Important Caveats

While sertraline itself does not cause false positives, be aware that:

  • Sampling position matters critically: Seated sampling increases false-positive rates regardless of medications 2
  • Other antidepressants do interfere: If a patient is on combination therapy including tricyclics or SNRIs (venlafaxine, duloxetine), these can cause false elevations 3
  • Urinary vs. plasma testing: The evidence specifically addresses plasma metanephrines; urinary metanephrines may have different interference patterns 4, 5

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.